Phaseline

Companies › Terrestrial Bio

Terrestrial Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VX-201
GLP-1 receptor agonist delivered via microneedle array patch
GLP1RPhase 1Overweight and/or ObesityFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07673900VX-201Phase 1Overweight and/or ObesityMetabolic and endocrineFeb 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

GLP1R (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.